For help on how to get the results you want, see our search tips.
1237 results
Categories
Human Remove Human filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Shortages Remove Shortages filter
Withdrawn applications Remove Withdrawn applications filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Jakavi (updated)
ruxolitinib (as phosphate), Myeloproliferative Disorders, Polycythemia Vera
Date of authorisation: 23/08/2012, Revision: 24, Authorised, Last updated: 04/08/2021 -
List item
Human medicine European public assessment report (EPAR): Imraldi (updated)
adalimumab, Hidradenitis Suppurativa, Psoriasis, Crohn Disease, Uveitis, Arthritis, Rheumatoid, Arthritis, Colitis, Ulcerative, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 24/08/2017,
, 
, Revision: 15, Authorised, Last updated: 04/08/2021
-
List item
Human medicine European public assessment report (EPAR): Lemtrada (updated)
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013,
, , Revision: 14, Authorised, Last updated: 04/08/2021
-
List item
Human medicine European public assessment report (EPAR): Pelmeg (updated)
pegfilgrastim, Neutropenia
Date of authorisation: 20/11/2018,, , Revision: 5, Authorised, Last updated: 04/08/2021
-
List item
Human medicine European public assessment report (EPAR): Opatanol (updated)
olopatadine hydrochloride, Conjunctivitis, Allergic
Date of authorisation: 16/05/2002, Revision: 21, Authorised, Last updated: 04/08/2021 -
List item
Human medicine European public assessment report (EPAR): COVID-19 Vaccine Janssen (updated)
adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S), COVID-19 virus infection
Date of authorisation: 11/03/2021,, 
, Revision: 6, Authorised, Last updated: 04/08/2021
-
List item
Human medicine European public assessment report (EPAR): Eylea (updated)
aflibercept, Wet Macular Degeneration, Macular Edema, Diabetes Complications
Date of authorisation: 21/11/2012, Revision: 22, Authorised, Last updated: 03/08/2021 -
List item
Human medicine European public assessment report (EPAR): Darzalex (updated)
Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016,, 
, 
, Revision: 16, Authorised, Last updated: 03/08/2021
-
List item
Human medicine European public assessment report (EPAR): Ifirmasta (previously Irbesartan Krka) (updated)
irbesartan hydrochloride, Hypertension
Date of authorisation: 01/12/2008,
, Revision: 14, Authorised, Last updated: 03/08/2021
-
List item
Human medicine European public assessment report (EPAR): Yervoy (updated)
Ipilimumab, Melanoma, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Malignant, Colorectal Neoplasms
Date of authorisation: 13/07/2011, Revision: 41, Authorised, Last updated: 03/08/2021 -
List item
Human medicine European public assessment report (EPAR): Ontozry (updated)
cenobamate, Epilepsy
Date of authorisation: 26/03/2021,, Revision: 2, Authorised, Last updated: 03/08/2021
-
List item
Human medicine European public assessment report (EPAR): Ninlaro (updated)
ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016,, , , Revision: 11, Authorised, Last updated: 03/08/2021
-
List item
Human medicine European public assessment report (EPAR): Nyvepria (updated)
pegfilgrastim, Neutropenia
Date of authorisation: 18/11/2020,, , Revision: 3, Authorised, Last updated: 03/08/2021
-
List item
Human medicine European public assessment report (EPAR): Opdivo (updated)
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Transitional Cell, Urologic Neoplasms, Mesothelioma, Colorectal Neoplasms
Date of authorisation: 19/06/2015, Revision: 43, Authorised, Last updated: 03/08/2021 -
List item
Human medicine European public assessment report (EPAR): Gilenya (updated)
fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011, Revision: 29, Authorised, Last updated: 03/08/2021 -
List item
Human medicine European public assessment report (EPAR): Phesgo (updated)
pertuzumab, trastuzumab, Breast Neoplasms
Date of authorisation: 21/12/2020,, Revision: 1, Authorised, Last updated: 03/08/2021
-
List item
Human medicine European public assessment report (EPAR): Calquence (updated)
Acalabrutinib, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 05/11/2020,, Revision: 1, Authorised, Last updated: 02/08/2021
-
List item
Human medicine European public assessment report (EPAR): Clopidogrel Krka d.d. (previously Zopya) (updated)
clopidogrel (as hydrochloride),
Date of authorisation: 20/09/2009,, Revision: 12, Authorised, Last updated: 30/07/2021
-
List item
Human medicine European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna) (updated)
CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021,, , Revision: 10, Authorised, Last updated: 30/07/2021
-
List item
Human medicine European public assessment report (EPAR): Mysildecard (updated)
sildenafil citrate, Hypertension, Pulmonary
Date of authorisation: 15/09/2016,, Revision: 4, Authorised, Last updated: 30/07/2021
-
List item
Human medicine European public assessment report (EPAR): Trumenba (updated)
Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily A; Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily B, Meningitis, Meningococcal
Date of authorisation: 24/05/2017,, Revision: 10, Authorised, Last updated: 30/07/2021
-
List item
Human medicine European public assessment report (EPAR): Byetta (updated)
exenatide, Diabetes Mellitus, Type 2
Date of authorisation: 20/11/2006, Revision: 25, Authorised, Last updated: 30/07/2021 -
List item
Human medicine European public assessment report (EPAR): Epidyolex (updated)
Cannabidiol, Lennox Gastaut Syndrome, Epilepsies, Myoclonic
Date of authorisation: 19/09/2019,, Revision: 8, Authorised, Last updated: 30/07/2021
-
List item
Human medicine European public assessment report (EPAR): Azacitidine Accord (updated)
azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 13/02/2020,, Revision: 2, Authorised, Last updated: 29/07/2021
-
List item
Human medicine European public assessment report (EPAR): Matever (updated)
levetiracetam, Epilepsy
Date of authorisation: 03/10/2011,, Revision: 23, Authorised, Last updated: 29/07/2021